Overview

Location [1]
21q22.3
Protein [2]
ICOS ligand
Synonyms [1]
B7H2, ICOSL, GL50, ICOS-L, B7-H2, CD275, B7h, LICOS, B7RP1, B7RP-1

ICOSLG is altered in 0.72% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, cutaneous melanoma, lung adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

ICOSLG GENIE Cases - Top Diseases

The most common alterations in ICOSLG are ICOSLG Amplification (0.18%), ICOSLG Loss (0.07%), ICOSLG Q106fs (0.02%), ICOSLG R194W (0.02%), and ICOSLG A254V (0.01%) [3].

ICOSLG GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.